PubMed Health⌕ Search

Biomedical subjects

T Rauscher

Publications and source records attributed to T Rauscher.

12 recordsLinked to original sources
PubMed2004

Neutron capture cross section measurement of 151Sm at the CERN neutron time of flight facility (n_TOF).

The151Sm(n,gamma)152Sm cross section has been measured at the spallation neutron facility n_TOF at CERN in the energy range from 1 eV to 1 MeV. The new facility combines excellent resolution in neutron time-of-flight, low repetition rates, and an unsurpassed instantaneous luminosity, resulting in rather favorable signal/background ratios. The 151Sm cross section is of importance for characterizing neutron capture nucleosynthesis in asymptotic giant branch stars. At a thermal energy of kT=30 keV the Maxwellian averaged cross section of this unstable isotope (t(1/2)=93 yr) was determined to be 3100+/-160 mb, significantly larger than theoretical predictions.

Journal Article↗
PubMed2001

End point of the rp process on accreting neutron stars.

We calculate the rapid proton ( rp) capture process of hydrogen burning on the surface of an accreting neutron star with an updated reaction network that extends up to Xe, far beyond previous work. In both steady-state nuclear burning appropriate for rapidly accreting neutron stars (such as the magnetic polar caps of accreting x-ray pulsars) and unstable burning of type I x-ray bursts, we find that the rp process ends in a closed SnSbTe cycle. This prevents the synthesis of elements heavier than Te and has important consequences for x-ray burst profiles, the composition of accreting neutron stars, and potentially galactic nucleosynthesis of light p nuclei.

Journal Article↗
PubMed2000

Time-dependent diagnostic performance of a rapid troponin T version 2 bedside test in patients with acute coronary syndromes.

In a prospective trial, the diagnostic performance of the second version of the troponin T rapid assay (Trop T; cutoff 0.2 microg/L) was compared with the quantitative cardiac-specific troponin T assay (cTnT ELISA; cutoff 0.1 microg/L) and other established cardiac markers such as CK, CK-MB activity, CK-MB mass and myoglobin. Additionally, a 30-day follow-up was performed to determine the suitability of the Trop T assay and the reference markers for short-term risk stratification. Two-hundred-and-eighty-six consecutive patients with chest pain and suspected acute myocardial infarction (AMI) were enrolled in two CCU departments. Serial blood specimens were taken at admission and at 3, 6, 12, 24, 48, 72 and 96 h after admission. According to the biochemical criterion CK-MB mass, the patients were classified as having AMI in 154 patients (54%), unstable angina (UAP) in 72 patients (27%) and no evidence for acute cardiac ischemia in 55 patients (19%). Analytical method comparison of Trop T with cTnT ELISA (cutoff 0.1 microg/L) showed a good agreement, Trop T yielded only 4% false-negative and 3% false-positive results. The diagnostic performance of Trop T for the detection of AMI was only slightly inferior compared to cTnT ELISA. Beyond 12 h after admission, Trop T and cTnT ELISA maintained a sensitivity close to 100%, whereas the sensitivity of the other cardiac markers decreased sharply. The diagnostic sensitivity of Trop T for the detection of minor myocardial damage in UAP patients was the same as for cTnT ELISA. Death within 30 days' follow-up occurred only in AMI patients with a positive Trop T test result within the first 6 h after admission. The admission Trop T and cTnT ELISA were the only significant biochemical predictors of major cardiac events. In conclusion, these data show that Trop T has similar diagnostic sensitivity as cTnT ELISA and is a useful tool to confirm acute or subacute myocardial infarction. Trop T is an excellent marker in detecting minor myocardial damage in UAP patients and is suitable for short-term risk stratification.

Angina, Unstable↗
PubMed1999

Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing.

BACKGROUND: In the evaluation of chest pain patients, whole blood bedside assays of highly specific cardiac molecules may be an attractive alternative to centralized clinical chemistry testing. We now report on an optimized test strip device for cardiac troponin T (cTnT) that can be analyzed by a cardiac reader for quantitative assessment of the test result. METHODS AND RESULTS: The cTnT test strip reader measures, via a CCD camera, the reflectance of the signal line. For quantitative analysis, a calibration curve was constructed from 1030 samples of 252 consecutive patients with acute coronary syndromes. In a method comparison of 140 samples, the quantitative results of the cTnT test strip reader correlated closely with the results of the cTnT ELISA (r = 0.98; y = 0.85x + 0. 002). Within-run and day-to-day (n = 10) mean CVs were between 11% and 16%, respectively. The cross-reactivity with skeletal troponin T was <0.02%. In patients with myocardial infarction, 45% and 91% of all samples were positive on admission and at 4-8 h after the onset of symptoms, respectively. ROC curve analysis demonstrated a comparable efficiency of the cTnT test strip reader and the laboratory-based cTnT ELISA in patients with suspected myocardial infarction. CONCLUSIONS: It is now possible to quantitatively determine cTnT at the patient's bedside with a rapid and convenient test device. This will facilitate the diagnostic work up of patients with suspected myocardial cell necrosis.

Angina, Unstable↗
PubMed1998

Clinical performance of the new cardiac markers troponin T and CK-MB on the Elecsys 2010. A multicentre evaluation.

Elecsys assays for the cardiac markers Troponin T (cTnT) and CK-MB have been evaluated in an international multicenter study on the random access analyzer Elecsys 2010 to characterize their clinical performance and their comparability with respective established routine methods. In method comparison studies of Elecsys Troponin T (TnT) with Enzymun-Test TnT, good correlations (r > or = 0.95) and a high degree of correspondence (slopes in 4 laboratories between 0.95 and 1.05) were found. The method comparison studies of Elecsys CK-MB with various CK-MB routine methods lead to good correlations but some systematic deviation in the slopes due to varying standardization. In a reference population of 350 persons upper reference limits (97.5th percentile) of 0.03 milligrams/l for Elecsys TnT and 3.1 milligrams/l for Elecsys CK-MB were found. In cardiosensitivity studies the equivalent diagnostic information of the new Elecsys assays to routine methods was confirmed in the early diagnosis of acute myocardial infarction (AMI), the detection of minor myocardial damages in patients with unstable angina pectoris (UAP) and in time course data monitoring of AMI and bypass surgery patients. The superior sensitivity of cTnT versus CK-MB has been established in a screening situation where in 29 patients with cardiac diseases only cTnT, but not CK-MB, was found pathologically increased; this was due either to the larger diagnostic window of cTnT in AMI or to the more sensitive recognition of minor myocardial damage. In the same study, the cardiospecificity of Elecsys TnT was found to be at least 99.5%. This has also been demonstrated in an earlier study for Enzymun-Test TnT. Further cardiospecificity testing, e.g. in renal failure patients, showed results equivalent to those of Enzymun-Test TnT. An extended clinical study involving 294 patients with chest pain, of whom 58 had a final diagnosis of AMI, revealed highly comparable sensitivity and specificity for the Elecsys assays and routine methods. Thus, the already recommended clinical cut-off values of 0.1 milligrams/l for cTnT and 5 milligrams/l for CK-MB are also valid for the Elecsys assays. The slightly improved sensitivity of Elecsys TnT in the lower range even allows the recognition of pathological increase at cTnT concentrations below 0.1 milligrams/l in special situations with sufficient additional clinical information. Summarizing, provide the two cardiac markers on the Elecsys 2010 at least equivalent or even superior diagnostic information in various clinical situations of cardiac disease compared with routine methods. The short turn-around time and reliable performance qualify the Elecsys assays as new methods of choice for routine and emergency use.

Adult↗
PubMed1993

[The biologic interaction of movements in the shoulder joint of cats and dogs].

The shoulder joint is a free joint which enables the free forelimb to describe curves in space, in order to perform movements and for locomotion. The movements can be measured in three planes: flexion-extension, abduction-adduction and rotation. The extent of movement in the cat, the German Shepherd and the Dachshund are described and the efficacy for these species and breeds is discussed.

Animals↗
PubMed1992

[The biological valence of the motion in the radioulnar joints of the cat and dog].

Whereas Kolwe described and measured pronation and supination in the cat as early as 1920, the present study deals with rotation of the lower limb of the cat and dog from both comparative and functional aspects. Active supination predominates in cats during climbing and the capture of prey; in the canine passive supination and rotation of the lower limb are used in conjunction with directional changes involved in the chase. The difference in the extent of inward rotation between long- and short-legged breeds of dogs underscores this hypothesis.

Animals↗
PubMed1984

Inhibitory and stimulating effects of various types and series of prostaglandins on in vitro biosynthesis of proteochondroitin-4,6-sulfate and protein and anaerobic glycolysis in calf rib cartilage.

The effect of various types of prostaglandins (PGs) have been studied in a semi-in-vitro system with cartilage slices of calf ribs. 0.1 mmol/1 PG B1, D2, E1, E2, F1 alpha, F2 alpha inhibit biosynthesis of Ch-4,6-S protein to a higher extent than 10 mumol/l; 1 and 2 series PG E and F (but not B) inhibit similarly, PG A2 inhibits twice as much. With biosynthesis of total protein 2-series PG A, B, E, F act more inhibitorily than 1-series PG. 10 mumol/l PG A2, E1, E2 produce cAMP-like effects, e.g. acceleration of biosynthesis of Ch-4,6-S protein and total protein as well as of anaerobic glycolysis; PG F2 alpha stimulates the first two anabolic processes, PG B1 only the second one. PG A1 stimulates Ch-4,6-S protein biosynthesis and anaerobic glycolysis, a cGMP-like effect. 20 mumol/l diBu-cAMP or cAMP (together with 0.1 mmol/l theophylline) produce stimulating and inhibitory effects on these three anabolic processes; both compounds produce additively positive or additively negative effects in connection with the inhibitory PG effects on these three anabolic processes.

Anaerobiosis↗